Wockhardt Limited (WOCKPHARMA) - Total Assets
Based on the latest financial reports, Wockhardt Limited (WOCKPHARMA) holds total assets worth Rs81.35 Billion INR (≈ $879.77 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check WOCKPHARMA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Wockhardt Limited - Total Assets Trend (2005–2025)
This chart illustrates how Wockhardt Limited's total assets have evolved over time, based on quarterly financial data. Explore WOCKPHARMA long-term investment intensity to see how much of total assets are deployed in long-term investments.
Wockhardt Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Wockhardt Limited's total assets of Rs81.35 Billion consist of 30.3% current assets and 69.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 2.4% |
| Accounts Receivable | Rs6.61 Billion | 8.1% |
| Inventory | Rs7.25 Billion | 8.9% |
| Property, Plant & Equipment | Rs22.31 Billion | 27.4% |
| Intangible Assets | Rs15.61 Billion | 19.2% |
| Goodwill | Rs9.77 Billion | 12.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Wockhardt Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Wockhardt Limited stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wockhardt Limited's current assets represent 30.3% of total assets in 2025, a decrease from 65.3% in 2005.
- Cash Position: Cash and equivalents constituted 2.4% of total assets in 2025, up from 0.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 4.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.4% of total assets.
Wockhardt Limited Competitors by Total Assets
Key competitors of Wockhardt Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Wockhardt Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 0.78 | 0.69 |
| Quick Ratio | 0.85 | 0.55 | 0.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs4.23 Billion | Rs-6.07 Billion | Rs-10.67 Billion |
Wockhardt Limited - Advanced Valuation Insights
This section examines the relationship between Wockhardt Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.79 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 6.4% |
| Total Assets | Rs81.35 Billion |
| Market Capitalization | $3.37 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Wockhardt Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Wockhardt Limited's assets grew by 6.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Wockhardt Limited (2005–2025)
The table below shows the annual total assets of Wockhardt Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs81.35 Billion ≈ $879.77 Million |
+6.35% |
| 2024-03-31 | Rs76.49 Billion ≈ $827.21 Million |
-0.44% |
| 2023-03-31 | Rs76.83 Billion ≈ $830.89 Million |
-6.79% |
| 2022-03-31 | Rs82.43 Billion ≈ $891.45 Million |
+6.05% |
| 2021-03-31 | Rs77.73 Billion ≈ $840.59 Million |
-4.97% |
| 2020-03-31 | Rs81.79 Billion ≈ $884.52 Million |
+4.44% |
| 2019-03-31 | Rs78.31 Billion ≈ $846.90 Million |
-4.05% |
| 2018-03-31 | Rs81.62 Billion ≈ $882.69 Million |
-8.99% |
| 2017-03-31 | Rs89.69 Billion ≈ $969.93 Million |
+12.78% |
| 2016-03-31 | Rs79.52 Billion ≈ $860.00 Million |
+14.60% |
| 2015-03-31 | Rs69.39 Billion ≈ $750.41 Million |
+4.78% |
| 2014-03-31 | Rs66.22 Billion ≈ $716.15 Million |
+9.64% |
| 2013-03-31 | Rs60.40 Billion ≈ $653.21 Million |
-3.42% |
| 2012-03-31 | Rs62.54 Billion ≈ $676.33 Million |
+6.20% |
| 2011-03-31 | Rs58.89 Billion ≈ $636.83 Million |
+2.84% |
| 2010-03-31 | Rs57.26 Billion ≈ $619.21 Million |
-14.90% |
| 2009-03-31 | Rs67.28 Billion ≈ $727.62 Million |
+30.56% |
| 2008-03-31 | Rs51.53 Billion ≈ $557.29 Million |
+38.74% |
| 2007-03-31 | Rs37.14 Billion ≈ $401.68 Million |
+72.84% |
| 2006-03-31 | Rs21.49 Billion ≈ $232.40 Million |
+11.99% |
| 2005-03-31 | Rs19.19 Billion ≈ $207.51 Million |
-- |
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more